ROCKVILLE, Md., Jan. 8, 2014 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of product candidates focused on the prevention and treatment of serious infectious and other diseases, announced today that Jeffrey Riley, CEO, is scheduled to present at the 7th Annual OneMedForum San Francisco 2014 conference next week in San Francisco, as follows: […]
ROCKVILLE, Md., Dec. 17, 2013 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of product candidates focused on the prevention and treatment of serious infectious and other diseases, today announced the closing of a previously announced underwritten public offering of 13,225,000 shares of its common stock, including the fully exercised over-allotment option by the
Synthetic Biologics Announces Closing of Public Offering of Common Stock Read More »
ROCKVILLE, Md., Dec. 13, 2013 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of product candidates focused on the prevention and treatment of serious infectious and other diseases, today announced the exercise of the over-allotment option granted to the underwriters to purchase an additional 1,725,000 shares of its common stock, at a price to the
Synthetic Biologics Announces Exercise of Underwriters’ Over-Allotment Option Read More »
ROCKVILLE, Md., Dec. 11, 2013 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of product candidates focused on the prevention and treatment of serious infectious and other diseases, announced today the pricing of an underwritten public offering of 11,500,000 shares of common stock at a public offering price of $1.00 per share. The Company
Synthetic Biologics Announces Pricing of Public Offering of Common Stock Read More »
ROCKVILLE, Md., Dec. 11, 2013 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of product candidates focused on the prevention and treatment of serious infectious and other diseases, announced today the pricing of an underwritten public offering of 11,500,000 shares of common stock at a public offering price of $1.00 per share. The Company
Synthetic Biologics Announces Pricing of Public Offering of Common Stock Read More »
ROCKVILLE, Md., Dec. 11, 2013 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of product candidates focused on the prevention and treatment of serious infectious and other diseases, announced today that it intends to offer for sale shares of its common stock in an underwritten public offering. The Company intends to use the net
Synthetic Biologics Announces Proposed Public Offering of Common Stock Read More »
— Webcast to be held Monday, December 9th at 9:00 a.m. EST — ROCKVILLE, Md., Dec. 7, 2013 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of product candidates focused on the prevention and treatment of serious infectious diseases and other diseases, announced today that it entered into worldwide license and option agreements with
ROCKVILLE, Md., Dec. 2, 2013 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, announced today that Jeffrey Riley, CEO, will present at the LD MICRO VI: Main Event Conference at 9:30 a.m. (PT) on Wednesday, December 4, 2013. The conference will be
Synthetic Biologics to Present at the LD MICRO VI: Main Event Conference in Los Angeles Read More »
— Company to Present at the 2013 Therapeutic Area Partnerships Conference — ROCKVILLE, Md., Nov. 14, 2013 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, today announced that SYN-004, Synthetic Biologics’ product candidate for the prevention of C. difficile infections, was selected
— Conference Call Today, November 14, at 10 a.m. Eastern Time — ROCKVILLE, Md., Nov. 14, 2013 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, today reported financial results for the three and nine months ended September 30, 2013 and provided an
Synthetic Biologics Reports Third Quarter 2013 Financial Results and Operational Update Read More »
